Shree Ganesh Remedies profitability ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
Returns
11.5%17.3%23.0%
8.9%12.7%16.5%
13.6%16.9%—
10.8%14.1%19.1%
Margins
32.0%36.1%33.2%
22.5%27.3%28.4%
−739.7%35.0%—
22.0%28.8%30.3%
16.3%21.3%22.3%
21.7%28.2%—
Additional
26.0%26.2%26.3%
11.5%17.3%23.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SGRL₹658.00

Shree Ganesh Remedies Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSHUKRAPHARSUNLOCMcap ₹845 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Returns
Return on Common Equity23.0317.2811.53
Return on Assets16.4512.738.89
Return on Capital Employed—16.8613.57
Return on Invested Capital19.0614.0910.82
Margins
EBITDA Margin33.2136.1132.04
Operating Margin28.3627.3022.46
Incremental Operating Margin—35.00-739.66
Pretax Margin30.3228.8221.97
Net Income Margin22.3321.2716.26
FCF Margin—28.2421.73
Additional
Effective Tax Rate26.3426.2025.99
Sustainable Growth Rate23.0317.2811.53
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.